Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia

OBJECTIVE Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.

[1]  M. Rickels,et al.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement , 2016, Transplantation.

[2]  S. Amiel,et al.  Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis , 2015, Diabetes Care.

[3]  M. Rickels,et al.  Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia , 2015, Diabetes Care.

[4]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[5]  N. Heaton,et al.  Outcomes for Adults with Type 1 Diabetes Referred with Severe Hypoglycaemia and/or Referred for Islet Transplantation to a Specialist Hypoglycaemia Service , 2014, Hormone and Metabolic Research.

[6]  Ahmad Haidar,et al.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[7]  B. Frier.  Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications , 2014, Nature Reviews Endocrinology.

[8]  P. Cryer.  Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia , 2014, Diabetes.

[9]  S. Heller,et al.  Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPaSS) , 2014, Diabetes Care.

[10]  D. Maahs,et al.  Frequency of Morning Ketosis After Overnight Insulin Suspension Using an Automated Nocturnal Predictive Low Glucose Suspend System , 2014, Diabetes Care.

[11]  S. Heller,et al.  A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study , 2014, Diabetes Care.

[12]  M. Rutter,et al.  Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  T. Jones,et al.  Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. , 2013, JAMA.

[14]  D. Klonoff,et al.  Threshold-based insulin-pump interruption for reduction of hypoglycemia. , 2013, The New England journal of medicine.

[15]  S. Grey,et al.  Multicenter Australian Trial of Islet Transplantation: Improving Accessibility and Outcomes , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  R. Beck,et al.  Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  R. Vigersky,et al.  Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society , 2013, Diabetes Care.

[18]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[19]  H. Kaneku.  2013 annual literature review of donor-specific HLA antibodies after organ transplantation. , 2013, Clinical transplants.

[20]  E. Bass,et al.  Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus , 2012, Annals of Internal Medicine.

[21]  N. Shah,et al.  Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia , 2012, Diabetes Care.

[22]  S. Heller,et al.  Improved Biomedical and Psychological Outcomes 1 Year After Structured Education in Flexible Insulin Therapy for People With Type 1 Diabetes , 2012, Diabetes Care.

[23]  M. Rickels,et al.  HLA Class I Sensitization in Islet Transplant Recipients: Report from the Collaborative Islet Transplant Registry 1 , 2010, Cell transplantation.

[24]  H. Kaneku.  2012 annual literature review of donor-specific HLA antibodies after organ transplantation. , 2012, Clinical transplants.

[25]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[26]  M. S. Kirkman,et al.  Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[27]  J. Dora,et al.  Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.

[28]  B. Frier,et al.  Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[29]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[31]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.

[32]  B. Hering,et al.  Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. , 2005, JAMA.

[33]  A. Shapiro,et al.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. , 2004, Diabetes.

[34]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[35]  D. C. Steen,et al.  The current state of pancreas transplantation. , 1999, AACN clinical issues.

[36]  D. Kendall,et al.  Pancreas Transplantation Restores Epinephrine Response and Symptom Recognition During Hypoglycemia in Patients With Long-Standing Type I Diabetes and Autonomic Neuropathy , 1997, Diabetes.

[37]  D. Cox,et al.  Reduced Awareness of Hypoglycemia in Adults With IDDM: A prospective study of hypoglycemic frequency and associated symptoms , 1995, Diabetes Care.

[38]  P. Cryer,et al.  Reversal of Hypoglycemia Unawareness, But Not Defective Glucose Counterregulation, in IDDM , 1994, Diabetes.

[39]  A. Maran,et al.  Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes , 1994, The Lancet.

[40]  Paolo Brunetti,et al.  Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM , 1993, Diabetes.

[41]  J. Halter,et al.  Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. , 1990, The Journal of clinical investigation.